NASDAQ:JNCE - Jounce Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$8.51 +0.36 (+4.42 %)
(As of 06/24/2018 04:00 PM ET)
Previous Close$8.51
Today's Range$8.04 - $8.55
52-Week Range$6.92 - $29.25
Volume626,939 shs
Average Volume1.21 million shs
Market Capitalization$264.74 million
P/E Ratio-14.93
Dividend YieldN/A
Beta5.55
Jounce Therapeutics logoJounce Therapeutics, Inc., a clinical stage immunotherapy company, develops therapies for the treatment of cancer. Its lead product candidate is JTX-2011, a clinical stage monoclonal antibody that binds to and activates the inducible T cell co-stimulator, a protein on the surface of certain T cells found in solid tumors, which is in Phase I/II clinical trial for the treatment of six tumor types, including head and neck squamous cell cancer, non-small cell lung cancer, triple negative breast cancer, melanoma, gastric cancer, and other tumor types identified through its translational science platform. The company is also developing JTX-4014, an anti-PD-1 antagonist antibody for combination therapy. Jounce Therapeutics, Inc. has a master research and collaboration agreement with Celgene Corporation focused on developing and commercializing biologic immunotherapies. The company was incorporated in 2012 and is headquartered in Cambridge, Massachusetts.

Receive JNCE News and Ratings via Email

Sign-up to receive the latest news and ratings for JNCE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:JNCE
CUSIPN/A
Phone857-259-3840

Debt

Debt-to-Equity RatioN/A
Current Ratio3.63
Quick Ratio3.63

Price-To-Earnings

Trailing P/E Ratio-14.93
Forward P/E Ratio-5.53
P/E GrowthN/A

Sales & Book Value

Annual Sales$71.64 million
Price / Sales3.86
Cash FlowN/A
Price / CashN/A
Book Value$5.18 per share
Price / Book1.64

Profitability

EPS (Most Recent Fiscal Year)($0.57)
Net Income$-16,440,000.00
Net Margins-47.73%
Return on Equity-19.90%
Return on Assets-10.22%

Miscellaneous

Employees112
Outstanding Shares32,480,000

The Truth About Cryptocurrencies

Jounce Therapeutics (NASDAQ:JNCE) Frequently Asked Questions

What is Jounce Therapeutics' stock symbol?

Jounce Therapeutics trades on the NASDAQ under the ticker symbol "JNCE."

How were Jounce Therapeutics' earnings last quarter?

Jounce Therapeutics Inc (NASDAQ:JNCE) posted its quarterly earnings results on Wednesday, May, 9th. The company reported ($0.40) EPS for the quarter, missing analysts' consensus estimates of ($0.31) by $0.09. The company earned $11.20 million during the quarter, compared to analyst estimates of $13.33 million. Jounce Therapeutics had a negative return on equity of 19.90% and a negative net margin of 47.73%. View Jounce Therapeutics' Earnings History.

When is Jounce Therapeutics' next earnings date?

Jounce Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, August, 7th 2018. View Earnings Estimates for Jounce Therapeutics.

What price target have analysts set for JNCE?

5 equities research analysts have issued 1-year price objectives for Jounce Therapeutics' stock. Their forecasts range from $10.00 to $20.00. On average, they expect Jounce Therapeutics' share price to reach $15.25 in the next year. View Analyst Ratings for Jounce Therapeutics.

Who are some of Jounce Therapeutics' key competitors?

Who are Jounce Therapeutics' key executives?

Jounce Therapeutics' management team includes the folowing people:
  • Dr. Richard Murray, Pres, CEO & Director (Age 59)
  • Ms. Kimberlee Cobleigh Drapkin, CFO, Treasurer & Principal Accounting Officer (Age 50)
  • Dr. Elizabeth G. Trehu M.D., Chief Medical Officer (Age 58)
  • Dr. James P. Allison Ph.D., Founder
  • Dr. Thomas F. Gajewski M.D., Ph.D., Founder

When did Jounce Therapeutics IPO?

(JNCE) raised $76 million in an initial public offering on Friday, January 27th 2017. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan and Cowen and Company acted as the underwriters for the IPO and Wells Fargo Securities and Baird were co-managers.

Has Jounce Therapeutics been receiving favorable news coverage?

Media stories about JNCE stock have trended somewhat negative this week, Accern reports. The research firm rates the sentiment of media coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Jounce Therapeutics earned a news sentiment score of -0.04 on Accern's scale. They also assigned media headlines about the company an impact score of 48.87 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next few days.

Who are Jounce Therapeutics' major shareholders?

Jounce Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Redmile Group LLC (3.64%), BlackRock Inc. (3.52%), Omega Fund Management LLC (1.63%), venBio Select Advisor LLC (1.61%), Citadel Advisors LLC (0.90%) and Fosun International Ltd (0.49%). Company insiders that own Jounce Therapeutics stock include Barbara Gayle Duncan, Celgene Switzerland Llc, Elizabeth Trehu, Hugh M Cole, John Duncan Higgons, Kimberlee C Drapkin and Richard /Ca/ Murray. View Institutional Ownership Trends for Jounce Therapeutics.

Which major investors are selling Jounce Therapeutics stock?

JNCE stock was sold by a variety of institutional investors in the last quarter, including Fosun International Ltd, Spark Investment Management LLC, Omega Fund Management LLC, Parsons Capital Management Inc. RI, Parsons Capital Management Inc. RI, BlackRock Inc., Russell Investments Group Ltd. and Northern Trust Corp. Company insiders that have sold Jounce Therapeutics company stock in the last year include Barbara Gayle Duncan, Elizabeth Trehu, Kimberlee C Drapkin and Richard /Ca/ Murray. View Insider Buying and Selling for Jounce Therapeutics.

Which major investors are buying Jounce Therapeutics stock?

JNCE stock was bought by a variety of institutional investors in the last quarter, including venBio Select Advisor LLC, Citadel Advisors LLC, Redmile Group LLC, Elephas Investment Management Ltd, Dimensional Fund Advisors LP, A.R.T. Advisors LLC, JBF Capital Inc. and Dynamic Technology Lab Private Ltd. Company insiders that have bought Jounce Therapeutics stock in the last two years include Celgene Switzerland Llc, Hugh M Cole and John Duncan Higgons. View Insider Buying and Selling for Jounce Therapeutics.

How do I buy shares of Jounce Therapeutics?

Shares of JNCE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Jounce Therapeutics' stock price today?

One share of JNCE stock can currently be purchased for approximately $8.51.

How big of a company is Jounce Therapeutics?

Jounce Therapeutics has a market capitalization of $264.74 million and generates $71.64 million in revenue each year. The company earns $-16,440,000.00 in net income (profit) each year or ($0.57) on an earnings per share basis. Jounce Therapeutics employs 112 workers across the globe.

How can I contact Jounce Therapeutics?

Jounce Therapeutics' mailing address is 780 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The company can be reached via phone at 857-259-3840.


MarketBeat Community Rating for Jounce Therapeutics (JNCE)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  130 (Vote Outperform)
Underperform Votes:  105 (Vote Underperform)
Total Votes:  235
MarketBeat's community ratings are surveys of what our community members think about Jounce Therapeutics and other stocks. Vote "Outperform" if you believe JNCE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe JNCE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.